In summary, PD-1/PD-L1 inhibitors appear to improve OS and have better tolerance compared to chemotherapy in the recurrence of advanced gastroesophageal carcinoma, especially for positive PD-L1 expression, squamous cell carcinoma, Asian region, esophageal cancer, second-line application, male, and 65 years of age or older patients. This evidence concerns the gene CD274 and esophageal cancer.